1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.03
D/E ratio less than half the Drug Manufacturers - Specialty & Generic median of 0.15. Benjamin Graham would praise this conservative approach, but check if excess equity dilutes returns.
9.50
Dangerously high net debt exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.36. Michael Burry would check for debt covenant compliance and refinancing risks.
-26.47
Negative coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
4.44
Current ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.66. Joel Greenblatt would verify if this conservative approach provides competitive advantages.
57.01%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 9.70%. Michael Burry would check for aggressive accounting and hidden risks.
